Free Trial

Lisa Walter Analyst Performance

Analyst at Royal Bank Of Canada

Lisa Walter is a stock analyst at Royal Bank Of Canada in the medical sector, covering 3 publicly traded companies. Over the past year, Lisa Walter has issued 3 stock ratings, including buy and hold recommendations. While full access to Lisa Walter's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Lisa Walter's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
3 Last 0 Years
Buy Recommendations
66.67% 2 Buy Ratings
Companies Covered
3 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy66.7%2 ratings
Hold33.3%1 ratings
Sell0.0%0 ratings

Out of 3 total stock ratings issued by Lisa Walter at Royal Bank Of Canada, the majority (66.7%) have been Buy recommendations, followed by 33.3% Hold.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
3 companies

Lisa Walter, an analyst at Royal Bank Of Canada, currently covers 3 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
3 companies
100.0%

Lisa Walter of Royal Bank Of Canada specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
3 companies
100.0%

Lisa Walter's Ratings History at Royal Bank Of Canada

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
8/7/2025Lower Price Target$16.72$41.00Outperform
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
8/1/2025Boost Price Target$23.05$19.00Sector Perform
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
6/17/2025Initiated Coverage$8.90$28.00Outperform